EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy

Yunus Emre Altıntaş iD, Oğuzcan Kınıkoğlu iD, Deniz Işık iD, Aziz Batu, Ayberk Bayramgil iD, Büşra Niğdelioğlu, Uğur Özkerim, Sıla Öksüz iD, Heves Sürmeli iD, Nedim Turan iD, Hatice Odabaş iD

Current Oncology · 2025

DOI: 10.3390/curroncol32090503 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Yunus Emre Altıntaş und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul 34865, Türkiye. Hauptthemen laut MEDLINE: Everolimus, Breast Neoplasms, Androstadienes, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hormone receptor-positive (HR+), HER2− negative metastatic breast cancer (MBC) is the most common subtype of advanced breast cancer. Resistance to endocrine therapy often develops, particularly after CDK4/6 inhibitors. Everolimus, an mTOR inhibitor, may restore hormone sensitivity, but real-world data after CDK4/6 and chemotherapy are limited.

Methods

This retrospective, single-center study included 70 patients with HR+/HER2− MBC who progressed on CDK4/6 inhibitors and at least one line of chemotherapy. All received daily oral everolimus (10 mg) plus exemestane (25 mg). Tumor response was assessed via RECIST v1.1, and survival outcomes were estimated using the Kaplan–Meier method.

Results

Median progression-free survival was 6.6 months and overall survival was 22.6 months. The disease control rate was 88.6%, with 57.1% showing partial response. Fatigue (20%), skin toxicity (8.6%), and stomatitis (5.7%) were the most common adverse events. No grade 3–4 toxicities or discontinuations occurred. No clinical or pathological variables significantly influenced survival.

Conclusions

Everolimus plus exemestane provided meaningful clinical benefit and manageable toxicity in heavily pretreated HR+/HER2− MBC patients. This regimen remains a valid later-line option, particularly in settings with limited access to newer targeted therapies or genomic testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EverolimusBreast NeoplasmsAndrostadienesAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedAgedRetrospective StudiesErb-b2 Receptor Tyrosine KinasesAdultCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Neoplasm MetastasisReceptors, EstrogenReceptors, ProgesteroneProtein Kinase Inhibitors

Stichwörter der Autor:innen

CDK4/6 inhibitor resistanceadvanced breast cancereverolimusexemestanemTOR inhibition

Substanzen

EverolimusAndrostadienesErb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Receptors, EstrogenReceptors, ProgesteroneProtein Kinase InhibitorsexemestaneERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul 34865, Türkiye.
  • Department of Medical Oncology, Ümraniye Training and Research Hospital, Istanbul 34760, Türkiye.

ORCID-Profile: Yunus Emre Altıntaş, Oğuzcan Kınıkoğlu, Deniz Işık, Ayberk Bayramgil, Sıla Öksüz, Heves Sürmeli, Nedim Turan, Hatice Odabaş

Zitieren

APA

Altıntaş, Y. E., Kınıkoğlu, O., Işık, D., Batu, A., Bayramgil, A., Niğdelioğlu, B., Özkerim, U., Öksüz, S., Sürmeli, H., Turan, N., & Odabaş, H. (2025). Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy. Current Oncology. https://doi.org/10.3390/curroncol32090503

Vancouver

Altıntaş YE, Kınıkoğlu O, Işık D, Batu A, Bayramgil A, Niğdelioğlu B, et al. Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy. Current Oncology. 2025. doi:10.3390/curroncol32090503

BibTeX
@article{Altnta2025,
  author = {Altıntaş, Yunus Emre and Kınıkoğlu, Oğuzcan and Işık, Deniz and Batu, Aziz and Bayramgil, Ayberk and Niğdelioğlu, Büşra and Özkerim, Uğur and Öksüz, Sıla and Sürmeli, Heves and Turan, Nedim and Odabaş, Hatice},
  title = {Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32090503}
}
Kostenlos starten →